Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriatic arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    225 result(s) found for: Psoriatic arthritis. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-003148-11 Sponsor Protocol Number: MoA-Ustekinumab Start Date*: 2015-01-29
    Sponsor Name:Academic Medical Center
    Full Title: Mechanism of action study of Ustekinumab treatment in psoriatic arthritis: Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling
    Medical condition: psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10066579 Progression of psoriatic arthritis LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10066730 Recurrent psoriatic arthritis LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10003377 Arthropathy psoriatic LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037161 Psoriatic arthritis aggravated LLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037162 Psoriatic arthropathy PT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037163 Psoriatic arthropathies HLT
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10037166 Psoriatic spondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002326-49 Sponsor Protocol Number: I1F-MC-RHAP Start Date*: 2013-11-05
    Sponsor Name:Eli Lilly & Company
    Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying ...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) BE (Completed) EE (Completed) BG (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000814-31 Sponsor Protocol Number: CAIN457F3302 Start Date*: 2016-08-03
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of sec...
    Medical condition: Axial Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FR (Completed) GB (Completed) HU (Completed) EE (Completed) IE (Completed) BE (Completed) FI (Completed) DK (Prematurely Ended) DE (Completed) BG (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002328-42 Sponsor Protocol Number: I1F-MC-RHBE Start Date*: 2015-01-21
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1F-MC-RHBE A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Diseas...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001773-90 Sponsor Protocol Number: MiCROBPsA Start Date*: 2020-03-10
    Sponsor Name:AZIENDA OSPEDALIERA SANT'ANDREA
    Full Title: Metagenomic analysis of the gut microbiota in patients with psoriatic arthritis upon treatment with the jak-stat inhibitor tofacitinib: correlations with immunological, clinical and imaging markers
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004940-31 Sponsor Protocol Number: IMM-12-0074 Start Date*: 2013-06-27
    Sponsor Name:Dept of medical sciences, Rheumatology
    Full Title: Dermal inflammation in psoriatic arthritis, the association to molecular mass of hyaluronan and effect of adalimumab. A prospective, open-label, multi-center study of hyaluronan molecular mass dis...
    Medical condition: Active psoriatic arthritis according to CASPAR
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003849-10 Sponsor Protocol Number: CAIN457F2336 Start Date*: 2015-03-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, saf...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) BE (Completed) BG (Completed) DE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000465-32 Sponsor Protocol Number: CNTO1959PSA4002 Start Date*: 2021-08-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriat...
    Medical condition: Active Psoriatic Arthritis Axial Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002433-22 Sponsor Protocol Number: I1F-MC-RHBF Start Date*: 2015-11-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter Study with a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period from Week 36 to Week 104 to Evaluate the Long Term Efficacy and Safety of Ixeki...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) CZ (Completed) GB (Completed) ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004002-25 Sponsor Protocol Number: CAIN457F2318 Start Date*: 2014-01-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tol...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed) NL (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000643-40 Sponsor Protocol Number: 50307 Start Date*: 2014-01-10
    Sponsor Name:Instituto de Medicina Molecular
    Full Title: A multicentre, randomized, double-blind, parallel–group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesi...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003637-14 Sponsor Protocol Number: GLPG0634-CL-224 Start Date*: 2017-01-26
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ...
    Medical condition: psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) ES (Completed) CZ (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-003554-25 Sponsor Protocol Number: 20090406 Start Date*: 2014-01-14
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-1
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) HU (Prematurely Ended) IT (Completed) GB (Prematurely Ended) ES (Prematurely Ended) SK (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004981-20 Sponsor Protocol Number: CNTO1959PSA3004 Start Date*: 2021-08-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhi...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) SI (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HR (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003405-94 Sponsor Protocol Number: ABY-035-202 Start Date*: 2020-05-05
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics a...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002804-29 Sponsor Protocol Number: PA0011 Start Date*: 2019-06-26
    Sponsor Name:UCB Biopharma SRL
    Full Title: A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004869-24 Sponsor Protocol Number: 20130207 Start Date*: 2015-12-09
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis.
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GR (Completed) GB (Completed) PT (Completed) HU (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003558-15 Sponsor Protocol Number: M14-197 Start Date*: 2015-07-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000972-91 Sponsor Protocol Number: CAIN457F3301 Start Date*: 2016-07-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of enthesitis at the Achilles tendon up to 1 year in adult pati...
    Medical condition: Psoriatic arthritis Axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018188 10037160 Psoriatic arthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) SK (Completed) CZ (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004254-22 Sponsor Protocol Number: PASTOR2018 Start Date*: 2020-03-20
    Sponsor Name:Charite University
    Full Title: Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Mult...
    Medical condition: Psoriatic Arthritis with axial (spinal) involvement
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037166 Psoriatic spondylitis LLT
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:29:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA